when the most ardent bear turns around and upgrades, that alone should point out that his thesis and sources are telling him that RLYP is going to win on this! The results from RLYP testing that shows its drug superior in use with chronic heart and kidney issues because of its lowering sodium levels is going to get big pharma jumping over each other to buy RLYP.
more testing will likely be required before FDA decided on chronic market. RLYP will fly on short squeeze and B.O. buyers will line up to grab RLYP. 50+
Do you really think 1.5 million fee is going to break a deal of 2 billion......come on that loan agreement is only a bargaining chip in getting the price RLYP wants.
25 to 30 in seconds
most speculators are out as shown by stock price, now is when it will likely happen!
sound familiar, hint VRX......
they would be stupid to borrow more! lol
DUBLIN (AP) _ Perrigo Co. (PRGO) on Thursday reported a loss of $133.1 million in its first quarter.
On a per-share basis, the Dublin-based company said it had a loss of 93 cents. Earnings, adjusted for one-time gains and costs, came to $1.75 per share.
The results missed Wall Street expectations. The average estimate of 18 analysts surveyed by Zacks Investment Research was for earnings of $1.83 per share.
The drug company posted revenue of $1.38 billion in the period, which beat Street forecasts. Seven analysts surveyed by Zacks expected $1.35 billion.
Perrigo expects full-year earnings in the range of $8.20 to $8.60 per share.
Perrigo shares have declined 36 percent since the beginning of the year, while the Standard & Poor's 500 index has increased 1 percent. The stock has fallen 52 percent in the last 12 months.
and then gave a range. from what i see it fell in their range at a much reduced level....thats not a beat!
They trying to sugar coat the fact that they have reduced their numbers dramatically twice in last 6 months?
Either way conference call should enlighten us on the write down that is coming.